Skip to main content

Development of new immunoassays for the diagnosis and prediction of drug-related complement pathology

Project description

Towards safer pharmaceuticals

Pharmaceuticals, including therapeutic antibodies, proteins and nanotechnology formulations, sometimes lead to severe and life-threatening conditions known as hypersensitivity reactions (HR). These emerge either due to a real allergic reaction driven by the release of IgE or because of a pseudoallergic condition triggered by the non-specific activation of the complement system. The latter triggers a massive acute inflammatory response associated with the release of cytokines, anaphylatoxins and cell-killing complexes. The EU-funded IMMUNOASSAYS project proposes to develop and evaluate promising biomarkers capable of discriminating between the different types of HR. These biomarkers could be employed for the safety assessment of new pharmaceuticals.


Net EU contribution
€ 174 806,40
Marie-curie-str. 1
53359 Rheinbach

See on map

Nordrhein-Westfalen Köln Rhein-Sieg-Kreis
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00